- new product
DxGen Corp. and Precision Diabetes, Inc. Announce Strategic Partnership to Launch New Diabetes Point-Of-Care Testing Analyzer into the U.S. Market.
RALEIGH, N.C. and SEOUL, Korea, Aug. 22, 2022 /PRNewswire/ -- Precision Diabetes, Inc. and DxGen Corp. are pleased to announce that they have entered in an exclusive agreement in the U.S. to launch Epithod® AutoDx, a fully-automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests. The initial test menu will begin with hemoglobin A1c (A1C), C-reactive protein, and urinary albumin, with additional diabetes...
Read more